Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2022
Price :
$35
*
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Neotope Biosciences; Prothena
- 18 Sep 2022 Results by deriving data from NCT02095171, NCT03100149, NCT04777331 and PPMI; developing Roche Digital Health Technology Platform to assess Disease Severity and Progression in Individuals with Parkinsons Disease, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 13 Dec 2016 Results published in the Prothena Corporation Media Release.
- 13 Dec 2016 According to Prothena Corporation media release, clinical results were published in Movement Disorders Journal.